Comments
Drug firm Wockhardt on Monday reported an over 11-fold jump in its consolidated net profit to ₹37.17 crore for the quarter-ended September 30, 2021.
The company had posted a net profit of ₹3.29 crore for the corresponding period of the previous fiscal, Wockhardt said in a regulatory filing.
Consolidated revenue of the company stood at ₹862 crore for the quarter under consideration. It was ₹714.05 crore in the year ago period, it added.
"Net debt-equity ratio as on September 30, 2021, stood at 0.54." the filing said.
UK business
The UK business grew by 66 per cent over the previous corresponding quarter and stood at ₹387 crore in Q2FY22. It contributed about 45 per cent of the global revenue, it added.
The continuing India business stood at ₹187 crore in the second quarter of FY22 registering growth of 47 per cent. It contributed 22 per cent of the global revenue, Wockhardt said.
"Research and development expenditure during the quarter was at ₹39 crore (5 per cent to sales) and including capital expenditure was at 7.4 per cent to sales," it added.
Three patents were filed during the quarter ended September 30, 2021, and the cumulative filings till date are 3,194. The company was granted 4 patents during the quarter and now holds 770 patents, Wockhardt said.
Shares of Wockhardt were trading at ₹464.30 per scrip on BSE, up 5.43 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.